|
1
|
Limper AH: Chemotherapy-induced lung
disease. Clin Chest Med. 25:53–64. 2004. View Article : Google Scholar
|
|
2
|
Graves PR, Siddiqui F, Anscher MS and
Movsas B: Radiation pulmonary toxicity: from mechanisms to
management. Semin Radiat Oncol. 20:201–207. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bhatia M, Zemans RL and Jeyaseelan S: Role
of chemokines in the pathogenesis of acute lung injury. Am J Respir
Cell Mol Biol. 46:566–572. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Martin TR and Matute-Bello G: Experimental
models and emerging hypotheses for acute lung injury. Crit Care
Clin. 27:735–752. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mukhopadhyay S, Hoidal JR and Mukherjee
TK: Role of TNFalpha in pulmonary pathophysiology. Respir Res.
7:1252006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Anscher MS: Targeting the TGF-beta1
pathway to prevent normal tissue injury after cancer therapy.
Oncologist. 15:350–359. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wilson MS, Madala SK, Ramalingam TR, et
al: Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A
dependent. J Exp Med. 207:535–552. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Blom IE, Goldschmeding R and Leask A: Gene
regulation of connective tissue growth factor: new targets for
antifibrotic therapy? Matrix Biol. 21:473–482. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Madala SK, Schmidt S, Davidson C, Ikegami
M, Wert S and Hardie WD: MEK-ERK pathway modulation ameliorates
pulmonary fibrosis associated with epidermal growth factor receptor
activation. Am J Respir Cell Mol Biol. 46:380–388. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Antoniou KM, Margaritopoulos GA, Soufla G,
et al: Expression analysis of Akt and MAPK signaling pathways in
lung tissue of patients with idiopathic pulmonary fibrosis (IPF). J
Recept Signal Transduct Res. 30:262–269. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jia X, Liu B, Shi X, Ye M, Zhang F and Liu
H: Roles of the ERK, JNK/AP-1/cyclin D1-CDK4 pathway in
silica-induced cell cycle changes in human embryo lung fibroblast
cells. Cell Biol Int. 35:697–704. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Morris GF: An alternative to lung
inflammation and fibrosis. Am J Pathol. 176:2595–2598. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vallabhapurapu S and Karin M: Regulation
and function of NF-kappaB transcription factors in the immune
system. Annu Rev Immunol. 27:693–733. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Johnson ER and Matthay MA: Acute lung
injury: epidemiology, pathogenesis, and treatment. J Aerosol Med
Pulm Drug Deliv. 23:243–252. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lamontagne F, Briel M, Guyatt GH, Cook DJ,
Bhatnagar N and Meade M: Corticosteroid therapy for acute lung
injury, acute respiratory distress syndrome, and severe pneumonia:
a meta-analysis of randomized controlled trials. J Crit Care.
25:420–435. 2010. View Article : Google Scholar
|
|
16
|
Raghu G, Collard HR, Egan JJ, et al: An
official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis:
evidence-based guidelines for diagnosis and management. Am J Respir
Crit Care Med. 183:788–824. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang D, Zhu J, Wang S, et al: Antitussive,
expectorant and anti-inflammatory alkaloids from Bulbus
Fritillariae Cirrhosae. Fitoterapia. 82:1290–1294. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang D, Wang S, Chen X, et al:
Antitussive, expectorant and anti-inflammatory activities of four
alkaloids isolated from Bulbus of Fritillaria wabuensis. J
Ethnopharmacol. 139:189–193. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Taooka Y, Maeda A, Hiyama K, Ishioka S and
Yamakido M: Effects of neutrophil elastase inhibitor on
bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care
Med. 156:260–265. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Aono Y, Nishioka Y, Inayama M, et al:
Imatinib as a novel antifibrotic agent in bleomycin-induced
pulmonary fibrosis in mice. Am J Respir Crit Care Med.
171:1279–1285. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Szapiel SV, Elson NA, Fulmer JD,
Hunninghake GW and Crystal RG: Bleomycin-induced interstitial
pulmonary disease in the nude, athymic mouse. Am Rev Respir Dis.
120:893–899. 1979.PubMed/NCBI
|
|
22
|
El-Demerdash E: Anti-inflammatory and
antifibrotic effects of methyl palmitate. Toxicol Appl Pharmacol.
254:238–244. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kim JW, Rhee CK, Kim TJ, et al: Effect of
pravastatin on bleomycin-induced acute lung injury and pulmonary
fibrosis. Clin Exp Pharmacol Physiol. 37:1055–1063. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hardie WD, Glasser SW and Hagood JS:
Emerging concepts in the pathogenesis of lung fibrosis. Am J
Pathol. 175:3–16. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhao L, Wang X, Chang Q, et al: Neferine,
a bisbenzylisoquinline alkaloid attenuates bleomycin-induced
pulmonary fibrosis. Eur J Pharmacol. 627:304–312. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu Y, Wu H, Nie YC, Chen JL, Su WW and Li
PB: Naringin attenuates acute lung injury in LPS-treated mice by
inhibiting NF-κB pathway. Int Immunopharmacol. 11:1606–1612.
2011.PubMed/NCBI
|
|
27
|
Lee HB, Kim EK, Park SJ, Bang SG, Kim TG
and Chung DW: Isolation and anti-inflammatory effect of astragalin
synthesized by enzymatic hydrolysis of tea seed extract. J Sci Food
Agric. 91:2315–2321. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fu PK, Wu CL, Tsai TH and Hsieh CL:
Anti-inflammatory and anticoagulative effects of paeonol on
LPS-induced acute lung injury in rats. Evid Based Complement
Alternat Med. 2012:8375132012.PubMed/NCBI
|
|
29
|
Lee JP, Li YC, Chen HY, et al: Protective
effects of luteolin against lipopolysaccharide-induced acute lung
injury involves inhibition of MEK/ERK and PI3K/Akt pathways in
neutrophils. Acta Pharmacol Sin. 31:831–838. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Soromou LW, Chen N, Jiang L, et al:
Astragalin attenuates lipopolysaccharide-induced inflammatory
responses by down-regulating NF-κB signaling pathway. Biochem
Biophys Res Commun. 419:256–261. 2012.PubMed/NCBI
|
|
31
|
Levings MK and Schrader JW: IL-4 inhibits
the production of TNF-alpha and IL-12 by STAT6-dependent and
-independent mechanisms. J Immunol. 162:5224–5229. 1999.PubMed/NCBI
|
|
32
|
Carey WA, Taylor GD, Dean WB and Bristow
JD: Tenascin-C deficiency attenuates TGF-β-mediated fibrosis
following murine lung injury. Am J Physiol Lung Cell Mol Physiol.
299:L785–L793. 2010.
|
|
33
|
Acloque H, Adams MS, Fishwick K,
Bronner-Fraser M and Nieto MA: Epithelial-mesenchymal transitions:
the importance of changing cell state in development and disease. J
Clin Invest. 119:1438–1449. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Xu J, Lamouille S and Derynck R:
TGF-beta-induced epithelial to mesenchymal transition. Cell Res.
19:156–172. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ramos C, Becerril C, Montano M, et al:
FGF-1 reverts epithelial-mesenchymal transition induced by
TGF-{beta}1 through MAPK/ERK kinase pathway. Am J Physiol Lung Cell
Mol Physiol. 299:L222–L231. 2010.PubMed/NCBI
|
|
36
|
Kono M, Nakamura Y, Suda T, et al: Plasma
CCN2 (connective tissue growth factor; CTGF) is a potential
biomarker in idiopathic pulmonary fibrosis (IPF). Clin Chim Acta.
412:2211–2215. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Leask A, Parapuram SK, Shi-Wen X and
Abraham DJ: Connective tissue growth factor (CTGF, CCN2) gene
regulation: a potent clinical bio-marker of fibroproliferative
disease? J Cell Commun Signal. 3:89–94. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dosreis GA, Borges VM and Zin WA: The
central role of Fas-ligand cell signaling in inflammatory lung
diseases. J Cell Mol Med. 8:285–293. 2004. View Article : Google Scholar : PubMed/NCBI
|
